Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

K, Tamura; I, Okamoto; T, Kashii; S, Negoro; T, Hirashima; S, Kudoh; Y, Ichinose; N, Ebi; K, Shibata; T, Nishimura; N, Katakami; T, Sawa; E, Shimizu; J, Fukuoka; T, Satoh; M, Fukuoka

doi:10.1038/sj.bjc.6604249

Public

Multicentre prospective phase II trial of gefitinib for advanced non-small cell lung cancer with epidermal growth factor receptor mutations: results of the West Japan Thoracic Oncology Group trial (WJTOG0403).

Shared by NobleBlocks on Feb 19, 2008 • 12:00 AM UTC

Authors:

Tamura K

Okamoto I

Kashii T

Abstract

The purpose of this study was to evaluate the efficacy of gefitinib and the feasibility of screening for epidermal growth factor receptor (EGFR) mutations among select patients with advanced non-small cell lung cancer (NSCLC). Stage IIIB/IV NSCLC, chemotherapy-naive patients or patients with recurre...

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!